A bill for an act relating to insurance coverage for prescription insulin drugs.
Summary
HF 405 would require certain health insurance policies, health maintenance organization contracts, and public employee health plans in Iowa that cover prescription drugs to cap a covered person’s out-of-pocket cost for insulin at no more than $25 per prescription fill for up to a 31-day supply. The cap would apply to at least one type of each major insulin category: rapid-acting, short-acting, intermediate-acting, and long-acting insulin. The bill defines insulin coverage terms, including “cost-sharing,” and allows insurers to charge less than the $25 cap if they choose.
The bill applies to policies and plans delivered, issued for delivery, continued, or renewed in Iowa on or after January 1, 2026. It also directs the insurance commissioner to adopt rules to administer the new requirements. Several types of coverage are excluded, including accident-only, specified disease, short-term hospital or medical, Medicare supplement, long-term care, dental, vision, workers’ compensation, and automobile medical payment coverage.
Impact
HF 405 would amend Iowa insurance law by creating a new section in chapter 514C that limits insulin-related cost-sharing in covered prescription drug plans. It would affect individual and group health insurance, hospital or medical service contracts, HMOs, and public employee health plans, while leaving many specialized or limited-benefit policies outside the mandate. Insurers and plan administrators would need to update benefit designs and claims systems to comply for policies renewed or issued on or after the effective applicability date.
Sentiment
The available context shows the bill was introduced and referred to the House Commerce Committee, but there are no recorded committee transcripts or votes in the provided materials. As a result, there is no documented floor or committee debate to indicate broad support or opposition. The bill’s structure suggests a consumer-protection approach aimed at lowering insulin costs for people with diabetes, which is typically framed positively in health coverage discussions.
Contention
The main policy issue embedded in the bill is the mandate itself: insurers and health plans would be required to limit insulin cost-sharing, which can raise concerns about premium impacts, benefit design flexibility, and administrative compliance. Another point of potential contention is the scope of coverage, because the bill applies only to plans that already cover prescription drugs and excludes several categories of insurance, which may lead to questions about uniform access and whether some enrollees remain outside the protection. No specific opponents or supporters are identified in the provided record.